| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 215 | 2023 | 5702 | 4.390 |
Why?
|
| Skin Neoplasms | 203 | 2023 | 5860 | 4.180 |
Why?
|
| Dysplastic Nevus Syndrome | 18 | 2014 | 59 | 1.260 |
Why?
|
| Nevus, Pigmented | 26 | 2017 | 222 | 1.130 |
Why?
|
| Sentinel Lymph Node Biopsy | 17 | 2020 | 734 | 1.070 |
Why?
|
| Nevus | 14 | 2016 | 205 | 1.040 |
Why?
|
| Neoplasm Staging | 50 | 2016 | 11218 | 0.950 |
Why?
|
| Dermatology | 14 | 2019 | 905 | 0.640 |
Why?
|
| Lentigo | 10 | 2004 | 37 | 0.600 |
Why?
|
| Lymph Nodes | 14 | 2015 | 3468 | 0.540 |
Why?
|
| Sunlight | 10 | 1998 | 336 | 0.530 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2019 | 392 | 0.510 |
Why?
|
| Skin Diseases | 9 | 2017 | 1084 | 0.490 |
Why?
|
| Biopsy | 25 | 2020 | 6779 | 0.420 |
Why?
|
| Pathology, Clinical | 3 | 2012 | 374 | 0.420 |
Why?
|
| Lymphatic Metastasis | 31 | 2016 | 2901 | 0.400 |
Why?
|
| Neoplasms, Multiple Primary | 10 | 2014 | 594 | 0.360 |
Why?
|
| Pigmentation Disorders | 10 | 1993 | 105 | 0.350 |
Why?
|
| Carcinoma, Merkel Cell | 4 | 2016 | 329 | 0.340 |
Why?
|
| Facial Dermatoses | 2 | 2004 | 87 | 0.330 |
Why?
|
| Melanocytes | 18 | 2014 | 509 | 0.320 |
Why?
|
| Pregnancy Complications, Neoplastic | 4 | 1999 | 260 | 0.320 |
Why?
|
| Ultraviolet Rays | 5 | 1998 | 1100 | 0.310 |
Why?
|
| Prognosis | 67 | 2023 | 29959 | 0.300 |
Why?
|
| Interferon-alpha | 5 | 2004 | 910 | 0.280 |
Why?
|
| Facial Neoplasms | 4 | 2004 | 126 | 0.260 |
Why?
|
| Precancerous Conditions | 4 | 2004 | 980 | 0.240 |
Why?
|
| Humans | 261 | 2023 | 766812 | 0.230 |
Why?
|
| Lymph Node Excision | 12 | 2015 | 1267 | 0.210 |
Why?
|
| Genes, p16 | 3 | 2010 | 158 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 4 | 2004 | 1062 | 0.180 |
Why?
|
| Skin Pigmentation | 6 | 1993 | 278 | 0.180 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2016 | 102 | 0.180 |
Why?
|
| Radiation Protection | 2 | 1998 | 425 | 0.170 |
Why?
|
| Middle Aged | 117 | 2018 | 223267 | 0.170 |
Why?
|
| Health Care Costs | 3 | 2017 | 3240 | 0.170 |
Why?
|
| Adult | 123 | 2017 | 223305 | 0.170 |
Why?
|
| Female | 152 | 2018 | 396532 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2011 | 4050 | 0.170 |
Why?
|
| Rosacea | 2 | 1992 | 60 | 0.160 |
Why?
|
| Consent Forms | 1 | 2019 | 55 | 0.160 |
Why?
|
| Lipomatosis, Multiple Symmetrical | 1 | 1998 | 8 | 0.160 |
Why?
|
| Cost of Illness | 3 | 2017 | 1949 | 0.160 |
Why?
|
| Sunscreening Agents | 3 | 1998 | 138 | 0.160 |
Why?
|
| Skin | 20 | 1998 | 4499 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 15 | 2014 | 3610 | 0.150 |
Why?
|
| Keratosis | 4 | 1995 | 81 | 0.150 |
Why?
|
| Male | 140 | 2018 | 364154 | 0.150 |
Why?
|
| Survival Rate | 16 | 2018 | 12826 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 1987 | 542 | 0.150 |
Why?
|
| Survival Analysis | 10 | 2014 | 10101 | 0.140 |
Why?
|
| Skin Aging | 2 | 1996 | 140 | 0.140 |
Why?
|
| Polyps | 2 | 1992 | 200 | 0.140 |
Why?
|
| Aged | 80 | 2018 | 171344 | 0.140 |
Why?
|
| Cholecystitis | 1 | 1997 | 181 | 0.130 |
Why?
|
| Arm | 5 | 2004 | 591 | 0.120 |
Why?
|
| Bowen's Disease | 1 | 1995 | 13 | 0.120 |
Why?
|
| Neoplasm Regression, Spontaneous | 2 | 1993 | 47 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 1997 | 190 | 0.120 |
Why?
|
| Doxepin | 1 | 1994 | 16 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 1374 | 0.110 |
Why?
|
| Laser Therapy | 2 | 1999 | 1108 | 0.110 |
Why?
|
| Risk Factors | 30 | 2016 | 74889 | 0.110 |
Why?
|
| False Negative Reactions | 3 | 2012 | 570 | 0.110 |
Why?
|
| Clobetasol | 1 | 1994 | 33 | 0.110 |
Why?
|
| Aged, 80 and over | 30 | 2016 | 59548 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 2902 | 0.110 |
Why?
|
| Lymphedema | 1 | 2000 | 526 | 0.110 |
Why?
|
| Microscopy | 3 | 1994 | 902 | 0.100 |
Why?
|
| Arthritis, Psoriatic | 1 | 2016 | 219 | 0.100 |
Why?
|
| Adolescent | 42 | 2018 | 88902 | 0.100 |
Why?
|
| Informed Consent | 1 | 2019 | 1010 | 0.100 |
Why?
|
| Nonprescription Drugs | 1 | 1994 | 119 | 0.100 |
Why?
|
| Antineoplastic Agents | 9 | 2016 | 13644 | 0.100 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2004 | 661 | 0.100 |
Why?
|
| Age Factors | 16 | 2018 | 18397 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2016 | 3552 | 0.100 |
Why?
|
| Hospitals, General | 2 | 2013 | 804 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2014 | 9407 | 0.100 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 2 | 2011 | 67 | 0.090 |
Why?
|
| Ear Neoplasms | 1 | 1992 | 118 | 0.090 |
Why?
|
| Massachusetts | 6 | 2015 | 8890 | 0.090 |
Why?
|
| Self-Examination | 4 | 2015 | 71 | 0.090 |
Why?
|
| Photography | 5 | 2001 | 536 | 0.090 |
Why?
|
| Pruritus | 1 | 1994 | 378 | 0.090 |
Why?
|
| Ear Canal | 1 | 1992 | 149 | 0.090 |
Why?
|
| History, 21st Century | 2 | 2010 | 1574 | 0.090 |
Why?
|
| Time Factors | 26 | 2012 | 40149 | 0.090 |
Why?
|
| Genital Diseases, Female | 1 | 1992 | 192 | 0.090 |
Why?
|
| Algorithms | 6 | 2017 | 14073 | 0.090 |
Why?
|
| Manuals as Topic | 1 | 2010 | 99 | 0.090 |
Why?
|
| Diagnosis, Differential | 14 | 2012 | 12985 | 0.090 |
Why?
|
| Cancer Vaccines | 3 | 2005 | 1042 | 0.090 |
Why?
|
| Metronidazole | 2 | 1992 | 237 | 0.090 |
Why?
|
| Leg Dermatoses | 1 | 1989 | 20 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2017 | 1248 | 0.080 |
Why?
|
| Penile Diseases | 1 | 1990 | 47 | 0.080 |
Why?
|
| Mycobacterium Infections | 2 | 1989 | 122 | 0.080 |
Why?
|
| Vulvar Diseases | 1 | 1990 | 64 | 0.080 |
Why?
|
| Back | 2 | 1988 | 64 | 0.080 |
Why?
|
| Incidence | 10 | 2017 | 21527 | 0.080 |
Why?
|
| United States | 22 | 2017 | 72945 | 0.080 |
Why?
|
| Retrospective Studies | 29 | 2020 | 81657 | 0.080 |
Why?
|
| Child | 28 | 2018 | 80670 | 0.080 |
Why?
|
| History, 20th Century | 2 | 2010 | 2764 | 0.080 |
Why?
|
| SEER Program | 3 | 2013 | 1444 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 1159 | 0.080 |
Why?
|
| Protective Devices | 1 | 1989 | 72 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 2783 | 0.080 |
Why?
|
| Risk Assessment | 11 | 2023 | 24299 | 0.080 |
Why?
|
| Mass Screening | 6 | 2003 | 5454 | 0.080 |
Why?
|
| BCG Vaccine | 3 | 1989 | 381 | 0.080 |
Why?
|
| Teaching | 1 | 1996 | 1171 | 0.080 |
Why?
|
| Boston | 7 | 2012 | 9346 | 0.080 |
Why?
|
| Triage | 2 | 2011 | 995 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2004 | 1469 | 0.070 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 1990 | 94 | 0.070 |
Why?
|
| Granuloma | 2 | 1989 | 329 | 0.070 |
Why?
|
| Head Protective Devices | 1 | 1989 | 118 | 0.070 |
Why?
|
| Follow-Up Studies | 21 | 2015 | 39312 | 0.070 |
Why?
|
| Epidemics | 1 | 2013 | 516 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2004 | 4523 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2000 | 705 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 746 | 0.070 |
Why?
|
| Dermatitis, Atopic | 1 | 1994 | 734 | 0.070 |
Why?
|
| Carotenoids | 5 | 1990 | 620 | 0.070 |
Why?
|
| Scalp | 2 | 1992 | 390 | 0.070 |
Why?
|
| Neoplasm Proteins | 3 | 2005 | 3600 | 0.070 |
Why?
|
| Sex Distribution | 4 | 2007 | 2274 | 0.070 |
Why?
|
| Neoplasm Metastasis | 15 | 2009 | 4892 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2001 | 8928 | 0.060 |
Why?
|
| Age Distribution | 4 | 2007 | 2869 | 0.060 |
Why?
|
| Cicatrix | 2 | 1990 | 798 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 7430 | 0.060 |
Why?
|
| Child, Preschool | 14 | 2018 | 42577 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2006 | 4056 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 1994 | 2252 | 0.060 |
Why?
|
| Choroid Neoplasms | 2 | 1986 | 177 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2233 | 0.060 |
Why?
|
| Hutchinson's Melanotic Freckle | 3 | 2011 | 26 | 0.060 |
Why?
|
| Health Education | 3 | 2015 | 1060 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2005 | 2841 | 0.060 |
Why?
|
| Tumor Burden | 4 | 2014 | 1902 | 0.060 |
Why?
|
| Neck | 2 | 1988 | 736 | 0.060 |
Why?
|
| Family Practice | 2 | 1998 | 508 | 0.060 |
Why?
|
| Germ-Line Mutation | 5 | 2010 | 1886 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 892 | 0.060 |
Why?
|
| Hypopigmentation | 2 | 2002 | 43 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2010 | 3446 | 0.060 |
Why?
|
| Amines | 2 | 2000 | 280 | 0.050 |
Why?
|
| Research Design | 2 | 1999 | 6206 | 0.050 |
Why?
|
| Siblings | 2 | 2006 | 828 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 3702 | 0.050 |
Why?
|
| Recombinant Proteins | 5 | 2004 | 6507 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 1992 | 1183 | 0.050 |
Why?
|
| Pedigree | 4 | 2010 | 4539 | 0.050 |
Why?
|
| Dermatomycoses | 3 | 1985 | 45 | 0.050 |
Why?
|
| Registries | 2 | 2013 | 8352 | 0.050 |
Why?
|
| Keratosis, Seborrheic | 1 | 2002 | 29 | 0.050 |
Why?
|
| Immunotherapy | 6 | 2005 | 4747 | 0.050 |
Why?
|
| Sex Factors | 8 | 2013 | 10619 | 0.050 |
Why?
|
| Office Visits | 1 | 2006 | 593 | 0.050 |
Why?
|
| Melphalan | 1 | 1984 | 425 | 0.050 |
Why?
|
| Point Mutation | 3 | 1998 | 1592 | 0.050 |
Why?
|
| Spectrophotometry | 2 | 2001 | 291 | 0.050 |
Why?
|
| Mohs Surgery | 1 | 2004 | 217 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 10384 | 0.050 |
Why?
|
| Pregnancy | 9 | 1999 | 30236 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2006 | 3485 | 0.050 |
Why?
|
| Psoriasis | 2 | 2006 | 925 | 0.050 |
Why?
|
| Porphyrias | 1 | 1981 | 57 | 0.050 |
Why?
|
| Interferons | 1 | 2005 | 716 | 0.050 |
Why?
|
| Risk | 10 | 2005 | 9602 | 0.050 |
Why?
|
| Monophenol Monooxygenase | 1 | 2001 | 72 | 0.050 |
Why?
|
| Ectropion | 1 | 1981 | 27 | 0.050 |
Why?
|
| Expert Systems | 1 | 2001 | 79 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 5536 | 0.050 |
Why?
|
| Vitamin E | 3 | 1990 | 872 | 0.040 |
Why?
|
| Infant | 9 | 2017 | 36459 | 0.040 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 1981 | 53 | 0.040 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 1983 | 231 | 0.040 |
Why?
|
| Patient Education as Topic | 3 | 2002 | 2334 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 3235 | 0.040 |
Why?
|
| Databases, Factual | 5 | 2016 | 8065 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2010 | 3957 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 2 | 1999 | 706 | 0.040 |
Why?
|
| Erythema | 3 | 2006 | 261 | 0.040 |
Why?
|
| Military Personnel | 1 | 1989 | 1260 | 0.040 |
Why?
|
| Emigration and Immigration | 2 | 1997 | 405 | 0.040 |
Why?
|
| Forecasting | 2 | 2002 | 2936 | 0.040 |
Why?
|
| Disease-Free Survival | 4 | 2014 | 6853 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2000 | 139 | 0.040 |
Why?
|
| Technetium | 1 | 1979 | 325 | 0.040 |
Why?
|
| Biopsy, Needle | 4 | 2007 | 1615 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 4 | 1995 | 565 | 0.040 |
Why?
|
| Homeopathy | 1 | 1999 | 30 | 0.040 |
Why?
|
| Patient Selection | 2 | 2010 | 4252 | 0.040 |
Why?
|
| Sulfur | 1 | 1979 | 158 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2004 | 1097 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 5367 | 0.040 |
Why?
|
| Glucosamine | 1 | 1979 | 128 | 0.040 |
Why?
|
| Clinical Trials as Topic | 4 | 2010 | 8045 | 0.040 |
Why?
|
| Acetates | 1 | 2000 | 314 | 0.040 |
Why?
|
| Levodopa | 2 | 1983 | 221 | 0.040 |
Why?
|
| Aspergillosis | 1 | 1980 | 242 | 0.040 |
Why?
|
| Evidence-Based Medicine | 3 | 2011 | 3692 | 0.040 |
Why?
|
| Sunburn | 3 | 1991 | 156 | 0.040 |
Why?
|
| Vitamin D | 1 | 1992 | 3270 | 0.040 |
Why?
|
| Estrogens | 1 | 1985 | 1528 | 0.040 |
Why?
|
| Young Adult | 8 | 2018 | 59939 | 0.040 |
Why?
|
| Hyperplasia | 4 | 1994 | 1150 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2019 | 2504 | 0.040 |
Why?
|
| Hyperhidrosis | 1 | 1978 | 34 | 0.040 |
Why?
|
| Cheek | 1 | 1998 | 66 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2001 | 949 | 0.040 |
Why?
|
| Spleen | 2 | 1984 | 2295 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 1997 | 1326 | 0.040 |
Why?
|
| Vitiligo | 3 | 1986 | 97 | 0.040 |
Why?
|
| Probability | 2 | 2005 | 2476 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2000 | 404 | 0.040 |
Why?
|
| Immunohistochemistry | 7 | 2005 | 11062 | 0.040 |
Why?
|
| Cohort Studies | 8 | 2018 | 41706 | 0.040 |
Why?
|
| Health Services Accessibility | 3 | 2011 | 5513 | 0.040 |
Why?
|
| Referral and Consultation | 3 | 2015 | 3618 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 1320 | 0.030 |
Why?
|
| Foot | 3 | 1997 | 576 | 0.030 |
Why?
|
| Censuses | 1 | 1998 | 198 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4114 | 0.030 |
Why?
|
| Dermoscopy | 1 | 2017 | 73 | 0.030 |
Why?
|
| Metals | 1 | 1981 | 711 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 1977 | 1838 | 0.030 |
Why?
|
| Monoamine Oxidase | 2 | 1967 | 179 | 0.030 |
Why?
|
| Antimanic Agents | 1 | 2000 | 523 | 0.030 |
Why?
|
| Vaccines | 1 | 2005 | 842 | 0.030 |
Why?
|
| Dendritic Cells | 2 | 2005 | 2747 | 0.030 |
Why?
|
| Methotrexate | 1 | 1983 | 1719 | 0.030 |
Why?
|
| Endometriosis | 2 | 1997 | 868 | 0.030 |
Why?
|
| World Health Organization | 1 | 2002 | 1327 | 0.030 |
Why?
|
| Lung Neoplasms | 3 | 2005 | 13489 | 0.030 |
Why?
|
| Medical Records | 1 | 2002 | 1408 | 0.030 |
Why?
|
| Hospital Charges | 1 | 1998 | 345 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2004 | 562 | 0.030 |
Why?
|
| Lymphokines | 1 | 1979 | 924 | 0.030 |
Why?
|
| Luminescent Measurements | 2 | 1994 | 342 | 0.030 |
Why?
|
| Observer Variation | 2 | 1993 | 2614 | 0.030 |
Why?
|
| Catecholamines | 1 | 1977 | 388 | 0.030 |
Why?
|
| Uveitis | 2 | 1986 | 398 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 1969 | 0.030 |
Why?
|
| Models, Biological | 6 | 2009 | 9464 | 0.030 |
Why?
|
| Lung | 1 | 1994 | 10068 | 0.030 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1994 | 56 | 0.030 |
Why?
|
| Prevalence | 3 | 2017 | 15835 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 1980 | 712 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 1974 | 84 | 0.030 |
Why?
|
| Hair Color | 2 | 1992 | 131 | 0.030 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2005 | 37 | 0.030 |
Why?
|
| Case-Control Studies | 7 | 2007 | 22248 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1977 | 556 | 0.030 |
Why?
|
| Dermatologic Agents | 1 | 1978 | 314 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2000 | 1139 | 0.030 |
Why?
|
| Models, Economic | 1 | 1998 | 719 | 0.030 |
Why?
|
| Hand | 3 | 1997 | 910 | 0.030 |
Why?
|
| Splenomegaly | 1 | 1974 | 191 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2017 | 597 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4570 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 1977 | 1180 | 0.030 |
Why?
|
| Skin Diseases, Infectious | 2 | 1985 | 75 | 0.030 |
Why?
|
| General Practitioners | 1 | 2015 | 103 | 0.030 |
Why?
|
| Alopecia | 1 | 1978 | 416 | 0.030 |
Why?
|
| Curriculum | 2 | 1998 | 3783 | 0.030 |
Why?
|
| Lymphocytes | 2 | 1998 | 2606 | 0.030 |
Why?
|
| Connecticut | 1 | 2013 | 365 | 0.030 |
Why?
|
| Bone Neoplasms | 5 | 2005 | 2561 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2005 | 5143 | 0.030 |
Why?
|
| Physicians, Family | 1 | 2015 | 348 | 0.030 |
Why?
|
| Prospective Studies | 14 | 2005 | 54872 | 0.030 |
Why?
|
| Skin Ulcer | 3 | 2000 | 131 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 1667 | 0.030 |
Why?
|
| beta Carotene | 4 | 1990 | 523 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 1994 | 712 | 0.020 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 20146 | 0.020 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 15425 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2002 | 2694 | 0.020 |
Why?
|
| Eczema | 1 | 1994 | 244 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 1057 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 4652 | 0.020 |
Why?
|
| Employment | 1 | 1998 | 1110 | 0.020 |
Why?
|
| Neoplasms | 3 | 2009 | 22350 | 0.020 |
Why?
|
| Acromegaly | 1 | 1974 | 316 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 2011 | 105 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 1998 | 1105 | 0.020 |
Why?
|
| Vasopressins | 1 | 1972 | 358 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1993 | 711 | 0.020 |
Why?
|
| Nail Diseases | 1 | 2011 | 54 | 0.020 |
Why?
|
| Actuarial Analysis | 3 | 1986 | 370 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2001 | 12795 | 0.020 |
Why?
|
| Statistics as Topic | 7 | 1997 | 2350 | 0.020 |
Why?
|
| Diet | 4 | 1992 | 8088 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 1788 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2011 | 164 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 1996 | 784 | 0.020 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 14653 | 0.020 |
Why?
|
| Sleep Stages | 1 | 1994 | 705 | 0.020 |
Why?
|
| Phenethylamines | 2 | 1967 | 95 | 0.020 |
Why?
|
| Phenotype | 3 | 2005 | 16722 | 0.020 |
Why?
|
| Public Health | 1 | 2023 | 2680 | 0.020 |
Why?
|
| Food Analysis | 1 | 1990 | 103 | 0.020 |
Why?
|
| Japan | 2 | 1996 | 1418 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 830 | 0.020 |
Why?
|
| Medicare | 2 | 2017 | 6813 | 0.020 |
Why?
|
| Combined Modality Therapy | 6 | 1997 | 8540 | 0.020 |
Why?
|
| Pigmentation | 3 | 1985 | 143 | 0.020 |
Why?
|
| Endometrium | 1 | 1992 | 406 | 0.020 |
Why?
|
| Methods | 3 | 1982 | 1065 | 0.020 |
Why?
|
| Income | 1 | 1998 | 1876 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1994 | 1741 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 1972 | 553 | 0.020 |
Why?
|
| Telemedicine | 1 | 2006 | 3111 | 0.020 |
Why?
|
| Infant, Newborn | 5 | 2017 | 26387 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 494 | 0.020 |
Why?
|
| Random Allocation | 3 | 1991 | 2394 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1993 | 1384 | 0.020 |
Why?
|
| Drug Costs | 1 | 2017 | 1194 | 0.020 |
Why?
|
| Physical Examination | 2 | 1986 | 1265 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 1990 | 305 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 1010 | 0.020 |
Why?
|
| Mathematics | 1 | 2009 | 696 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 622 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 588 | 0.020 |
Why?
|
| Immune Tolerance | 3 | 1987 | 2328 | 0.020 |
Why?
|
| Macrophages | 3 | 1998 | 5784 | 0.020 |
Why?
|
| Anus Neoplasms | 1 | 1992 | 336 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 15912 | 0.020 |
Why?
|
| Penetrance | 1 | 2010 | 388 | 0.020 |
Why?
|
| Butylamines | 1 | 1967 | 9 | 0.020 |
Why?
|
| Retinoblastoma | 1 | 1990 | 321 | 0.020 |
Why?
|
| Ethylamines | 1 | 1967 | 17 | 0.020 |
Why?
|
| Radionuclide Imaging | 3 | 1999 | 1986 | 0.020 |
Why?
|
| Population Surveillance | 1 | 1998 | 2594 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15831 | 0.020 |
Why?
|
| Health Surveys | 1 | 2017 | 4055 | 0.020 |
Why?
|
| Xeroderma Pigmentosum | 1 | 1987 | 31 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 1994 | 12430 | 0.020 |
Why?
|
| Abortion, Spontaneous | 1 | 1992 | 536 | 0.020 |
Why?
|
| Dacarbazine | 1 | 1990 | 552 | 0.020 |
Why?
|
| Logistic Models | 2 | 2016 | 13276 | 0.020 |
Why?
|
| Hysterectomy | 1 | 1992 | 863 | 0.020 |
Why?
|
| Recurrence | 3 | 1998 | 8507 | 0.020 |
Why?
|
| Propylamines | 1 | 1967 | 161 | 0.020 |
Why?
|
| Eye Diseases | 2 | 1986 | 660 | 0.020 |
Why?
|
| Biological Specimen Banks | 1 | 2012 | 787 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 2 | 1999 | 282 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 3230 | 0.020 |
Why?
|
| Epidermis | 2 | 1993 | 539 | 0.020 |
Why?
|
| Acute Disease | 1 | 1997 | 7240 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 5 | 2000 | 2930 | 0.020 |
Why?
|
| Terminal Care | 1 | 1998 | 1769 | 0.020 |
Why?
|
| Syndrome | 2 | 1985 | 3271 | 0.020 |
Why?
|
| Guinea Pigs | 3 | 1986 | 1309 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1987 | 642 | 0.020 |
Why?
|
| PUVA Therapy | 1 | 1986 | 101 | 0.020 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1987 | 187 | 0.020 |
Why?
|
| Intraoperative Care | 2 | 2000 | 768 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1994 | 1163 | 0.020 |
Why?
|
| Intestinal Neoplasms | 3 | 1983 | 314 | 0.020 |
Why?
|
| Dicarboxylic Acids | 1 | 1985 | 75 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2005 | 223 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2005 | 207 | 0.020 |
Why?
|
| Multivariate Analysis | 4 | 2003 | 12064 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 21162 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2017 | 2520 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 1276 | 0.010 |
Why?
|
| Ontario | 1 | 2005 | 403 | 0.010 |
Why?
|
| Vaccination | 1 | 1997 | 3435 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 1999 | 63 | 0.010 |
Why?
|
| Financing, Personal | 1 | 2006 | 310 | 0.010 |
Why?
|
| HLA Antigens | 2 | 1982 | 1339 | 0.010 |
Why?
|
| Medicaid | 1 | 2017 | 2836 | 0.010 |
Why?
|
| Flow Cytometry | 3 | 2005 | 5890 | 0.010 |
Why?
|
| Reoperation | 1 | 2014 | 4325 | 0.010 |
Why?
|
| Actins | 1 | 1991 | 2061 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2001 | 7869 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 1988 | 1365 | 0.010 |
Why?
|
| Treatment Outcome | 5 | 2012 | 65286 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 1445 | 0.010 |
Why?
|
| Educational Status | 1 | 1991 | 2510 | 0.010 |
Why?
|
| Proportional Hazards Models | 3 | 2004 | 12536 | 0.010 |
Why?
|
| Foot Diseases | 2 | 1982 | 148 | 0.010 |
Why?
|
| Beta-Globulins | 1 | 1982 | 27 | 0.010 |
Why?
|
| Dermatitis, Exfoliative | 1 | 1983 | 28 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1996 | 4926 | 0.010 |
Why?
|
| Sarcoma | 1 | 1994 | 1802 | 0.010 |
Why?
|
| Breast | 1 | 1992 | 1972 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2000 | 5130 | 0.010 |
Why?
|
| Case Management | 1 | 2005 | 276 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 896 | 0.010 |
Why?
|
| Liver Neoplasms | 3 | 2005 | 4356 | 0.010 |
Why?
|
| Regression Analysis | 3 | 1992 | 6329 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 1990 | 1737 | 0.010 |
Why?
|
| Pyrimidine Dimers | 1 | 1982 | 19 | 0.010 |
Why?
|
| Australia | 1 | 1986 | 1263 | 0.010 |
Why?
|
| MART-1 Antigen | 1 | 2002 | 62 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2013 | 2519 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1985 | 504 | 0.010 |
Why?
|
| Mortality | 1 | 2013 | 2908 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6514 | 0.010 |
Why?
|
| Social Class | 1 | 1991 | 2007 | 0.010 |
Why?
|
| Genetic Engineering | 2 | 1998 | 936 | 0.010 |
Why?
|
| Argyria | 1 | 1981 | 2 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1982 | 330 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1641 | 0.010 |
Why?
|
| Phenothiazines | 1 | 1981 | 60 | 0.010 |
Why?
|
| Bismuth | 1 | 1981 | 28 | 0.010 |
Why?
|
| Proteins | 1 | 1996 | 6002 | 0.010 |
Why?
|
| Smoking | 3 | 1990 | 9077 | 0.010 |
Why?
|
| Clofazimine | 1 | 1981 | 39 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2006 | 1186 | 0.010 |
Why?
|
| Tetracyclines | 1 | 1981 | 64 | 0.010 |
Why?
|
| Disease Progression | 2 | 2015 | 13642 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 10745 | 0.010 |
Why?
|
| Community-Institutional Relations | 1 | 2002 | 209 | 0.010 |
Why?
|
| Photosensitivity Disorders | 1 | 1981 | 79 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1984 | 376 | 0.010 |
Why?
|
| Consensus | 1 | 2010 | 3208 | 0.010 |
Why?
|
| Cell Separation | 1 | 2005 | 1718 | 0.010 |
Why?
|
| Geography | 1 | 1982 | 651 | 0.010 |
Why?
|
| Carcinogens | 1 | 1982 | 452 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 2004 | 634 | 0.010 |
Why?
|
| Abdomen | 1 | 2006 | 1137 | 0.010 |
Why?
|
| TRPM Cation Channels | 1 | 2001 | 140 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2846 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 1983 | 335 | 0.010 |
Why?
|
| Amiodarone | 1 | 1981 | 216 | 0.010 |
Why?
|
| Colloids | 1 | 1979 | 125 | 0.010 |
Why?
|
| Remission Induction | 1 | 2005 | 2413 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1998 | 6105 | 0.010 |
Why?
|
| Microchemistry | 1 | 1979 | 54 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1981 | 618 | 0.010 |
Why?
|
| Iritis | 1 | 1978 | 15 | 0.010 |
Why?
|
| Vitamin A | 1 | 1982 | 611 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1987 | 1384 | 0.010 |
Why?
|
| Leg | 1 | 1984 | 1087 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2000 | 412 | 0.010 |
Why?
|
| Bandages | 1 | 1980 | 270 | 0.010 |
Why?
|
| Porphyrins | 1 | 1981 | 352 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 1981 | 559 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1987 | 1161 | 0.010 |
Why?
|
| Miliaria | 1 | 1978 | 6 | 0.010 |
Why?
|
| Mercury | 1 | 1981 | 289 | 0.010 |
Why?
|
| Alcohol Drinking | 2 | 1990 | 4045 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2013 | 4306 | 0.010 |
Why?
|
| Lead Poisoning | 1 | 1981 | 323 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 3803 | 0.010 |
Why?
|
| Occlusive Dressings | 1 | 1978 | 52 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1985 | 1791 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 4914 | 0.010 |
Why?
|
| Aging | 2 | 1991 | 8728 | 0.010 |
Why?
|
| Iron | 2 | 1990 | 1812 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2002 | 1093 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1990 | 3208 | 0.010 |
Why?
|
| Age of Onset | 2 | 1996 | 3343 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1998 | 325 | 0.010 |
Why?
|
| Arsenic | 1 | 1981 | 357 | 0.010 |
Why?
|
| Plastics | 1 | 1978 | 117 | 0.010 |
Why?
|
| Aluminum | 1 | 1978 | 150 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1998 | 491 | 0.010 |
Why?
|
| Gold | 1 | 1981 | 482 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 1424 | 0.010 |
Why?
|
| Color | 2 | 1993 | 297 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1993 | 8623 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 3530 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 3157 | 0.010 |
Why?
|
| Culture Media | 1 | 1979 | 893 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 1892 | 0.010 |
Why?
|
| Imidazoles | 1 | 1983 | 1168 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1994 | 9244 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 1996 | 84 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2003 | 1196 | 0.010 |
Why?
|
| Animals | 7 | 1998 | 168939 | 0.010 |
Why?
|
| Codon | 1 | 1998 | 599 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1976 | 317 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2001 | 904 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 1986 | 1560 | 0.010 |
Why?
|
| Primary Prevention | 1 | 1983 | 1188 | 0.010 |
Why?
|
| Chlorides | 1 | 1978 | 666 | 0.010 |
Why?
|
| Herpes Zoster | 2 | 1983 | 252 | 0.010 |
Why?
|
| Hemangioma | 2 | 1993 | 727 | 0.010 |
Why?
|
| Salivary Gland Diseases | 1 | 1974 | 37 | 0.010 |
Why?
|
| Diploidy | 1 | 1994 | 140 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1996 | 534 | 0.010 |
Why?
|
| Antimalarials | 1 | 1981 | 909 | 0.010 |
Why?
|
| S100 Proteins | 1 | 1995 | 215 | 0.010 |
Why?
|
| Antioxidants | 1 | 1982 | 1671 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 1998 | 0.010 |
Why?
|
| Feces | 1 | 1981 | 1505 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1996 | 640 | 0.010 |
Why?
|
| Vimentin | 1 | 1995 | 257 | 0.010 |
Why?
|
| Base Sequence | 2 | 1996 | 12415 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 18076 | 0.010 |
Why?
|
| Gaucher Disease | 1 | 1974 | 110 | 0.010 |
Why?
|
| Cell Nucleus | 2 | 1994 | 2875 | 0.010 |
Why?
|
| Skin Tests | 1 | 1976 | 630 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1996 | 748 | 0.010 |
Why?
|
| Eosinophils | 1 | 1998 | 952 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2000 | 1127 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 4347 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2001 | 2931 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1998 | 2127 | 0.010 |
Why?
|
| Computational Biology | 1 | 2005 | 3564 | 0.010 |
Why?
|
| Pigments, Biological | 1 | 1993 | 52 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 11657 | 0.010 |
Why?
|
| Salivary Glands | 1 | 1974 | 231 | 0.010 |
Why?
|
| ROC Curve | 1 | 2001 | 3621 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1994 | 217 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1974 | 527 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1999 | 2659 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1993 | 766 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1974 | 234 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 17609 | 0.010 |
Why?
|
| Hyperpigmentation | 1 | 1994 | 116 | 0.010 |
Why?
|
| Piperazines | 1 | 1983 | 2547 | 0.010 |
Why?
|
| Diabetes Insipidus | 1 | 1972 | 144 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1967 | 2478 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1996 | 1494 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2001 | 2021 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 2826 | 0.010 |
Why?
|
| Conjunctival Neoplasms | 1 | 1992 | 78 | 0.010 |
Why?
|
| Exons | 1 | 1998 | 2392 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1996 | 903 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1991 | 110 | 0.010 |
Why?
|
| Atlases as Topic | 1 | 1993 | 247 | 0.010 |
Why?
|
| Odds Ratio | 2 | 1997 | 9661 | 0.010 |
Why?
|
| Melanosis | 1 | 1992 | 93 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1994 | 573 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1983 | 3464 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 13036 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1991 | 529 | 0.010 |
Why?
|
| Infertility, Female | 1 | 1997 | 763 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 1990 | 128 | 0.010 |
Why?
|
| Rabbits | 2 | 1967 | 4752 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 2005 | 9101 | 0.010 |
Why?
|
| Extremities | 2 | 1986 | 869 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1972 | 635 | 0.010 |
Why?
|
| Cell Division | 1 | 1997 | 4473 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2001 | 5306 | 0.010 |
Why?
|
| Cell Nucleolus | 1 | 1990 | 156 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 2703 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1998 | 1266 | 0.010 |
Why?
|
| Kinetics | 2 | 1967 | 6288 | 0.010 |
Why?
|
| Binding Sites | 1 | 1998 | 6013 | 0.000 |
Why?
|
| Mutation | 1 | 1993 | 30214 | 0.000 |
Why?
|
| DNA | 1 | 1982 | 7210 | 0.000 |
Why?
|
| Keratinocytes | 1 | 1993 | 876 | 0.000 |
Why?
|
| Liver | 2 | 1984 | 7571 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1996 | 2925 | 0.000 |
Why?
|
| Decision Making | 1 | 2001 | 3951 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1991 | 2275 | 0.000 |
Why?
|
| Genetic Testing | 1 | 2000 | 3591 | 0.000 |
Why?
|
| Glucose | 1 | 1979 | 4340 | 0.000 |
Why?
|
| Alcohols | 1 | 1967 | 94 | 0.000 |
Why?
|
| Mescaline | 1 | 1966 | 7 | 0.000 |
Why?
|
| Tyramine | 1 | 1966 | 55 | 0.000 |
Why?
|
| Heterozygote | 1 | 1993 | 2795 | 0.000 |
Why?
|
| Dermatitis, Seborrheic | 1 | 1986 | 7 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 4780 | 0.000 |
Why?
|
| Cross-Sectional Studies | 2 | 2003 | 26309 | 0.000 |
Why?
|
| Collagen | 1 | 1994 | 2635 | 0.000 |
Why?
|
| Pregnancy Complications | 1 | 1980 | 2971 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1996 | 4249 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 2535 | 0.000 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1993 | 1457 | 0.000 |
Why?
|
| Prototheca | 1 | 1985 | 3 | 0.000 |
Why?
|
| Transfer Factor | 1 | 1985 | 5 | 0.000 |
Why?
|
| Levamisole | 1 | 1985 | 36 | 0.000 |
Why?
|
| Propionibacterium acnes | 1 | 1985 | 59 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1976 | 5502 | 0.000 |
Why?
|
| Amphotericin B | 1 | 1985 | 140 | 0.000 |
Why?
|
| Retinal Perforations | 1 | 1986 | 138 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1985 | 11876 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1971 | 1497 | 0.000 |
Why?
|
| Parkinson Disease | 1 | 1978 | 2884 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6066 | 0.000 |
Why?
|
| Uveal Diseases | 1 | 1983 | 45 | 0.000 |
Why?
|
| Paraffin | 1 | 1983 | 36 | 0.000 |
Why?
|
| Cytokines | 1 | 1998 | 7438 | 0.000 |
Why?
|
| Blister | 1 | 1983 | 88 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1979 | 18986 | 0.000 |
Why?
|
| Nocardia Infections | 1 | 1983 | 19 | 0.000 |
Why?
|
| Ketoconazole | 1 | 1983 | 95 | 0.000 |
Why?
|
| Histological Techniques | 1 | 1983 | 193 | 0.000 |
Why?
|
| Melanins | 1 | 1985 | 291 | 0.000 |
Why?
|
| Bacterial Vaccines | 1 | 1985 | 400 | 0.000 |
Why?
|
| Image Enhancement | 1 | 1993 | 2858 | 0.000 |
Why?
|
| Debridement | 1 | 1985 | 494 | 0.000 |
Why?
|
| Insulin | 1 | 1977 | 6608 | 0.000 |
Why?
|
| Connective Tissue Diseases | 1 | 1985 | 285 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1984 | 1478 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 10263 | 0.000 |
Why?
|
| Pectoralis Muscles | 1 | 1981 | 86 | 0.000 |
Why?
|
| Depression | 1 | 2000 | 8225 | 0.000 |
Why?
|
| Head | 1 | 1986 | 926 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1983 | 2551 | 0.000 |
Why?
|
| Candidiasis | 1 | 1983 | 372 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1993 | 8728 | 0.000 |
Why?
|
| Herpes Simplex | 1 | 1983 | 470 | 0.000 |
Why?
|
| Dopamine | 1 | 1966 | 1581 | 0.000 |
Why?
|
| Cell Movement | 1 | 1991 | 5204 | 0.000 |
Why?
|
| Quality of Life | 1 | 2001 | 13476 | 0.000 |
Why?
|
| Thrombosis | 1 | 1993 | 2953 | 0.000 |
Why?
|
| Forearm | 1 | 1981 | 425 | 0.000 |
Why?
|
| Pseudomonas Infections | 1 | 1983 | 622 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1985 | 1390 | 0.000 |
Why?
|
| Fundus Oculi | 1 | 1977 | 560 | 0.000 |
Why?
|
| Hypertension | 1 | 1974 | 8616 | 0.000 |
Why?
|
| Monocytes | 1 | 1982 | 2599 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1971 | 307 | 0.000 |
Why?
|
| Immunity, Innate | 1 | 1983 | 3079 | 0.000 |
Why?
|
| Heart Failure | 1 | 1974 | 11879 | 0.000 |
Why?
|
| Graft Rejection | 1 | 1983 | 4504 | 0.000 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1985 | 3633 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1981 | 3317 | 0.000 |
Why?
|
| Kidney Transplantation | 1 | 1983 | 4278 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1985 | 7475 | 0.000 |
Why?
|
| Inflammation | 1 | 1982 | 10863 | 0.000 |
Why?
|
| Mice | 1 | 1986 | 81898 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1977 | 20710 | 0.000 |
Why?
|